Haleon PLC Advances Share Buyback Program with New Purchase

Haleon PLC ( (GB:HLN) ) has provided an announcement.

Haleon PLC announced the purchase of 1,500,000 ordinary shares as part of its share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and could influence shareholder decisions regarding their interests in the company.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes categories such as Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 20,352,730

Technical Sentiment Signal: Sell

Current Market Cap: £29.45B

Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.